A Pharmaceutical Powerhouse Pivots: Pfizer Embraces Trump's 'Most Favored Nation' Pricing
Trump's Landmark Drug Price Promise: A Deadline Vanished, Unnoticed
Novartis Plots Strategic Price Adjustments in US as Trump's MFN Deadline Looms